CoChat

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

Open access
Yilmaz, Yusuf, Eren, Fatih, Yonal, Oya, Kurt, Ramazan, Aktas, Bilge, Celikel, Cigdem Ataizi, Ozdogan, Osman, Imeryuz, Nese, Kalayci, Cem, Avsar, Erol · 2010 · European Journal of Clinical Investigation
Cited by 195

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Eur J Clin Invest 2010; 40 (10): 887–892 Background The fibroblast growth factor 21 (FGF21) hormonal pathway is a metabolic signalling cascade and has been recently identified as the master hormonal regulator of glucose, lipids and overall energy balance. In this observational, case–control study, we assayed serum levels of FGF21 in patients with nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, and examined their association with clinical, biochemical and histological phenotypes. Materials and methods Serum levels of FGF21 were assayed by ELISA in 82 patients with biopsy‐proven NAFLD and 77 controls. We analysed associations between FGF21 and the characteristics of patients with NAFLD by multiple linear regression analysis. Results Levels of FGF21 were significantly higher in patients with NAFLD (median 200 pg mL−1; interquartile range: 87–410 pg mL−1) than in healthy controls (median 93 pg mL−1; interquartile range: 70–180 pg mL−1, Mann–Whitney U‐test, P < 0·001). There was a stepwise increase in serum FGF21 levels according to the liver steatosis score (median level in subjects with score 1: 170 pg mL−1; score 2: 220 pg mL−1; score 3: 280 pg mL−1, P for trend < 0·01). After stepwise linear regression analysis, serum FGF21 levels were the only independent predictor of hepatic steatosis scores in patients with NAFLD (β = 0·26; t = 2·659, P < 0·01). Conclusions Serum FGF21 levels are increased in patients with NAFLD regardless of potential confounders and represent an independent predictor of liver steatosis. These findings support further investigation of this molecule in metabolic liver diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.2010.02338.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 195

Metadata

Authors
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C. A., Ozdogan, O., Imeryuz, N., Kalayci, C., & Avsar, E.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2010-08-19
Volume
40
Issue
10
Pages
887-892
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W1515671273
Cited by
195
References
12
FWCI
4.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/j.1365-2362.2010.02338.x
The paper
Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Aktas, B., Celikel, C. A., Ozdogan, O., Imeryuz, N., Kalayci, C., & Avsar, E. (2010). Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2010.02338.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.